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Anti-Tumor Activity and 
Immunotherapeutic Potential of a 
Bisphosphonate Prodrug
Yoshimasa Tanaka1,2,3, Masashi Iwasaki1, Kaoru Murata-Hirai1, Kenji Matsumoto1, Kosuke 
Hayashi1, Haruki Okamura4, Tomoharu Sugie5, Nagahiro Minato2, Craig T. Morita6 & 
Masakazu Toi5
Bisphosphonates have benefits in breast cancer and multiple myeloma patients and have been used 
with adoptive immunotherapy with γδ T cells expressing Vγ2 Vδ2 TCRs. Although treatment with γδ 
T cells is safe, it has shown limited efficacy. Present bisphosphonates stimulate γδ T cells but were 
designed to inhibit bone resorption rather than treating cancer and have limited oral absorption, 
tumor cell entry, and cause bone side effects. The development of phosphate and phosphonate 
nucleotide prodrugs has led to important drugs for hepatitis C and HIV. Using a similar approach, 
we synthesized bisphosphonate prodrugs and found that they efficiently limit tumor cell growth. 
Pivoxil bisphosphonate esters enter cells where esterases convert them to their active acids. The 
bisphosphonate esters stimulated γδ T cells to secrete TNF-α in response to a variety of tumor cells 
more efficiently than their corresponding acids. The most active compound, tetrakis-pivaloyloxymethyl 
2-(thiazole-2-ylamino)ethylidene-1,1- bisphosphonate (7), specifically expanded γδ T cells and 
stimulated them to secrete interferon-γ and kill tumor cells. In preclinical studies, combination therapy 
with compound 7 and γδ T cells prolonged survival of mice inoculated with either human bladder cancer 
or fibrosarcoma cells. Therefore, bisphosphonate prodrugs could enhance the effectiveness of adoptive 
cancer immunotherapy with γδ T cells.
Geminal bisphosphonates with P-C-P structure were initially developed as anti-corrosion agents for industrial 
purposes1. The first-generation bisphosphonates such as etidronate and clodronate show high affinity for bone 
minerals and are metabolized to cytotoxic β, γ-methylene analogs of ATP in osteoclasts2. Extensive synthetic 
efforts resulted in second-generation bisphosphonates with alkylamine side chains and third-generation bisphos-
phonates with nitrogen-containing heterocyclic side chains for the treatment of patients with osteoporosis and 
hypercalcemia of malignancy3.
These nitrogen-containing bisphosphonates enter monocyte-lineage cells (including osteoclasts) as well as 
tumor cells where they inhibit farnesyl diphosphate synthase (FDPS)4, 5. FDPS inhibition reduces the levels of 
its downstream metabolites, farnesyl diphosphate (FPP) and geranylgeranyl diphosphate (GGPP), and leads to 
the production of a toxic ATP analog, triphosphoric acid 1-adenosin-5′-yl ester 3-(3-methylbut-3-enyl) ester 
(ApppI)6. The loss of FDPS metabolites impairs their transfer to the C-termini of small GTPases, such as RAS, 
RAP, RHO, and RAB, and the γ subunit of G protein-coupled receptors, that is required for their functions in 
signal transduction and cell survival.
Inhibition of FDPS also leads to the accumulation of its upstream metabolite, isopentenyl pyrophosphate 
(diphosphate) (IPP)7–9, which in turn stimulates cytotoxic γδ T cells through their Vγ2 Vδ2 TCRs by the sensing 
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of IPP binding to the B30.2 domain of butyrophilin (BTN) 3A110–14. These activated γδ T cells exhibit potent 
cytotoxic activity against bisphosphonates-pulsed tumor cells15.
The addition of intravenous zoledronic acid to standard therapies improves disease-free survival of breast 
cancer patients in a low estrogen environment16–18 and overall survival of multiple myeloma patients19 and lung 
cancer patients20. The use of oral bisphosphonates (alendronate or risedronate) also improves survival of breast 
cancer patients21. The anti-tumor activity of bisphosphonates is likely mediated through several pathways; one 
possible pathway is by promoting the anti-tumor activity of γδ T cells.
γδ T cells bearing Vγ2 Vδ2 TCRs have been targeted for cancer immunotherapy in two ways. In one approach, 
Vγ2Vδ2 T cells are directly stimulated in vivo either by an IPP analog or an aminobisphosphonates in conjunc-
tion with IL-222–26. This approach has had limited success because expansion of Vγ2Vδ2 T cell does not always 
occur and because deletion and/or anergy of Vγ2Vδ2 T cells rapidly develops. A second approach has been the ex 
vivo expansion of Vγ2Vδ2 T cells followed by their adoptive transfer27–36. This approach avoids the development 
of anergy by harvesting and freezing of PBMC prior to therapy or by avoiding the use of intravenous bisphos-
phonates. However, the most successful clinical trials have used intravenous zoledronic acid around the time of 
adoptive transfer of Vγ2Vδ2 T cells.
One potential way to improve γδ T cell immunotherapy is to increase the potency of the bisphosphonate 
used by facilitating tumor cell entry. Oldfield and co-workers have improved the activity of bisphosphonates by 
incorporating long acyl chains37, 38 or by masking the P-C-P structure with pivoxil esters39. Pivoxil bisphospho-
nate esters have also been used to inhibit geranylgeranyl diphosphate synthase40. Similar masking of the negative 
charges of the phosphate moieties of nucleotides to make prodrugs has greatly improved their effectiveness in 
treating hepatitis C and human immunodeficiency virus infections41, 42.
We recently synthesized pivaloyloxymethyl (pivoxil) derivatives of bisphosphonates43. The resulting bisphos-
phonate prodrugs were efficiently internalized into tumor cells where intracellular esterases converted them into 
biologically active bisphosphonic acids that block FDPS. FDPS inhibition slows tumor growth through inhibition 
of prenylation of signal transduction molecules (schematic is shown in Fig. 1). Blocking of FDPS will also increase 
IPP levels in tumor cells which should make them stimulatory for Vγ2Vδ2 T cells through their Vγ2 Vδ2 TCRs.
In this study, we have assessed the ability of these bisphosphonate prodrugs to stimulate γδ T cells and to 
inhibit prenylation in a variety of tumor cell lines. Bisphosphonate prodrugs potently stimulated γδ T cells with 
pretreatment of the different cell lines. A thiazole bisphosphonate prodrug, 7, showed the highest potency for 
stimulation of γδ T cells and inhibition of RAP1A prenylation. 7 specifically stimulated Vγ2Vδ2 T cells to expand 
from blood lymphocytes, secrete IFN-γ, and kill tumor cells. In preclinical studies, 7 combined with Vγ2Vδ2 T 
cells prolonged survival of immunodeficient NOG mice implanted with either human bladder cancer or fibrocar-
cinoma cells more than Vγ2Vδ2 T cells alone.
Results
Enhancement of TNF-α secretion from γδ T cells by pivaloyloxymethylation of bisphospho-
nates. We previously showed that masking the phosphonate charges of bisphosphonates by pivoxil groups 
greatly enhanced their ability to inhibit tumor cell growth43. To determine if the stimulation of Vγ2Vδ2 T cells 
showed similar enhancement, EJ-1 bladder carcinoma cells were treated with seven bisphosphonate prodrugs 
or their corresponding active acid forms (Supplemental Fig. S1). Five of these pairs (2–6/9–13) were based on 
NE11809 (compound 8)44, 45. A final compound substituted a thiazole for the pyridine group. Their synthesis has 
been described43. All of the bisphosphonate prodrugs stimulated TNF-α secretion from γδ T cells more effectively 
than their corresponding acid forms (Fig. 2). For example, compound 7 was 1,100-fold more active than its acid, 
14 (Fig. 2D). Bisphosphonate prodrug concentrations required to stimulate half-maximal TNF-α production 
(EC50) from γδ T cells were between 20-fold to 1,100-fold lower than their acid forms (Supplemental Table S1) 
with several (5, 6, and 7) active at less than 80 nM. These differences were larger than the values we previously 
reported for growth inhibition of EJ-1 cells with eight of the nine pivoxil esters active at lower concentrations43.
Based on these findings, we tested 28 additional bisphosphonate pivoxil and other esters (compounds 15–42, 
Supplemental Fig. S2) for their ability to stimulate TNF-α release by γδ T cells. Again 7 was the most potent 
although its methyl- derivative (34) had similar activity as did compound 39, another analog of 8, that is similar 
in structure and potency to 5 and 6 (Supplemental Table S2). Given that compound 7 was the most active for γδ 
T cell activation and tumor growth inhibition43, we focused on it for further study.
γδ T cell activation by compound 7. 7 was also more active than its acid form, 14, in stimulating release 
of TNF-α by Vγ2Vδ2 T cells upon testing an additional 21 tumor cell lines, ranging from 81-fold to 1,900-fold 
more potent (Table 1 and Supplemental Fig. S3). 7 was further tested against a variety of tumor cell lines in com-
parison to zoledronic acid, the most potent FDA-approved bisphosphonate (Fig. 3 and Supplemental Table S3). 
The EC50 values for most tumor cell lines were less than 1 μM (Fig. 3) and 76 out of 77 tumor cell lines elic-
ited TNF-α responses by Vγ2Vδ2 T cells. The proportion of tumor cell lines with EC50 values of 100 nM or less 
was 57.1% for lymphoma, 85.7% for myeloid leukemia, 14.3% for mammary carcinoma, and 51.9% for other 
tumor cell lines. The average EC50 ± S.D. was 157 ± 170 nM for lymphomas, 96 ± 91 nM for myeloid leukemias, 
465 ± 290 nM for mammary carcinomas, and 298 ± 240 nM for other tumor cell lines. These values were signifi-
cantly lower than those for zoledronic acid, where the average EC50 ± S.D. was 367,571 ± 173,160 nM (2,337-fold 
greater than that of compound 7) for lymphomas, 240,571 ± 219,133 nM (2,495-fold) for myeloid leukemias, 
187,771 ± 191,657 nM (404-fold) for mammary carcinomas, and 52,223 ± 82,697 nM (190-fold) for other tumor 
cell lines46. Thus, 7 is a significantly more potent activator of γδ T cells than zoledronic acid.
Inhibition of RAP1A-geranylgeranylation in tumor cells by compound 7. Bisphosphonates indi-
rectly stimulate Vγ2Vδ2 T cells by inhibiting FDPS resulting in the intracellular accumulation of IPP, its upstream 
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metabolite. The binding of IPP to the B30.2 domain of BTN3A1 alters cells in an undefined way to make them 
stimulatory for Vγ2Vδ2 T cells7, 9. Additionally, downstream metabolites such as geranylgeranyl diphosphate and 
farnesyl diphosphophate, are depleted leading to the accumulation of unprenylated RAP1A, a small G protein 
required for cellular adhesion. Therefore, the accumulation of unprenylated RAP1A is a measure of FDPS inhibi-
tion (Supplemental Fig. S4). To confirm that 7 uses the same mechanism of action as other bisphosphonates, the 
concentration of compound 7 required for half-maximal inhibition (IC50) of RAP1A prenylation was determined 
for a variety of tumor cell lines (Fig. 4 and Supplemental Table S3). 7 was highly active at inhibiting the prenyla-
tion of RAP1A with six cell lines with IC50 values < 10 nM, the P31/FUJ and MONO-1 monocyte-like leukemia 
cells, the EJ-1 and T24 bladder carcinoma cells, the 786-0 renal cell carcinoma cells, and the KATOIII gastric 
carcinoma cells. The proportion of tumor cell lines with an IC50 of 100 nM or less was 71.4% for lymphoma, 85.7% 
for myeloid leukemias, 42.9% for mammary carcinomas, and 32.7% for other tumor cell lines (Fig. 4). The average 
IC50 ± S.D. were similar to those noted for stimulating TNF-α release with values of 115 ± 115 nM for lympho-
mas, 107 ± 197 nM for myeloid leukemias, 1,099 ± 1,965 nM for mammary carcinomas, and 386 ± 259 nM for 
other tumor cell lines. Again, the values for zoledronic acid, were much higher than those for 7 (Fig. 4D), with 
an average IC50 ± S.D. of 372,286 ± 164,995 nM (3,233-fold greater than that of compound 7) for lymphomas, 
281,129 ± 229,049 nM (2,626-fold) for myeloid leukemias, 163,143 ± 191,842 nM (149-fold) for mammary car-
cinomas, and 64,249 ± 172,850 nM (166-fold) for other tumor cell lines46. Therefore, similar to the EC50 values 
noted for stimulating TNF-α release, 7 was a highly potent inhibitor of RAP1A prenylation. Given that most 
strong inhibitors of GGPS have mono- or diacyl- chains to occupy the farensyl and/or the geranyl sites47–49, the 
activity of 7 is likely due to inhibition of FDPS.
Figure 1. Schematic diagram of intracellular conversion of bisphosphonate pivoxil prodrugs to their 
corresponding acids. Bisphosphonate prodrugs are taken up by tumor cells where intracellular esterases remove 
their pivaloyloxymethyl moieties to yield their acid forms. The active acid forms inhibit FDPS resulting in 
increases in an upstream metabolite, IPP, that stimulate Vγ2Vδ2 T cells and decreases in downstream farensyl 
diphosphate and geranylgeranyl diphosphate resulting in decreased prenylation of signaling proteins inhibiting 
tumor cell growth and function.
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To assess the degree of correlation between compound 7 activities, the concentrations of compound 7 required 
for γδ T cell activation (EC50) were correlated with those for FDPS inhibition (IC50) or for tumor growth inhi-
bition for each of the tumor cell lines (Supplemental Table S3). Only tumor cell growth inhibition and TNF-α 
release (r = 0.282, p = 0.016) were significantly correlated for compound 7 (Supplemental Fig. S5, top left panel). 
The concentrations of compound 7 required to stimulate production of TNF-α release were not significantly 
correlated with those required for RAP1A inhibition nor were tumor cell growth inhibition and RAP1A inhi-
bition correlated. In contrast, zoledronic acid exhibited highly significant correlations for cell inhibition and 
TNF-α stimulation (r = 0.454, p < 0.0001), cell inhibition and RAP1A inhibition (r = 0.556, p < 0.0001), and 
TNF-α stimulation and RAP1A inhibition (r = 0.499, p < 0.0001). Also, 7 and zoledronic acid activities were not 
significantly correlated (Supplemental Fig. S5). Because the pivoxil esters must be removed to activate 7, the lack 
of correlation between most activities of 7 could reflect differences in esterase expression in the tumor cell lines 
or other factors besides FDPS inhibition that determine its activity. The activity of zoledronic acid, in contrast, 
is likely dependent primarily on FDPS inhibition. Hence, the high correlation for the three activities measured.
Specific stimulation of γδ T cells expressing Vγ2 Vδ2 TCRs by compound 7. To assess the specific-
ity of stimulation by compound 7, PBMC were cultured with 7 and the levels of Vγ2Vδ2 T cells determined after 
14 days. Despite the presence of other γδ and αβ T cells, only Vγ2Vδ2 T cells were selectively expanded to 98.8% 
of cells (Fig. 5A). The expansion of Vγ2Vδ2 T cells also demonstrates that compound 7 is not severely toxic to 
monocytes given that this response is dependent on their activity50, 51. To determine the specificity of compound 
7 on cellular cytotoxicity of γδ T cells, their activity against T-47D mammary carcinoma cells was tested in a 
real-time cell growth assay. Exposure of T-47D mammary carcinoma cells to 50 nM of compound 7 did not affect 
their growth while exposure to γδ T cells slightly delayed their growth. In contrast, the addition of both com-
pound 7 and γδ T cells to cultures of T-47D cells inhibited their growth in a compound 7 dose-dependent manner 
(Fig. 5B). Additionally, pretreatment of U937 histocytoma cells with compound 7 rendered them stimulatory 
for Vγ2Vδ2 T cell degranulation and surface expression of CD107a (Fig. 5C). Finally, compound 7 stimulated 
Figure 2. TNF-α secretion by γδ T cells stimulated with tumor cells pretreated with BP prodrugs and 
their acids. TNF-α production by γδ T cells in response to EJ-1 bladder cancer cells pretreated with various 
concentrations of bisphosphonate prodrugs was compared with that in response to EJ-1 bladder cancer cells 
pretreated with their corresponding acids: (A) compounds 3 (⚫) and 10 (⚪), (B) 5 (⚫) and 12 (⚪), (C) 6 (⚫) 
and 13 (⚪), (D) 7 (⚫) and 14 (⚪).
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Vγ2Vδ2 T cells in PBMC to release interferon-γ (IFN-γ) (Fig. 5D). These results demonstrate that γδ T cells 
expressing Vγ2 Vδ2 TCRs are specifically activated to proliferate, kill tumor cells, and release IFN-γ by exposure 
to monocytes and tumor cells treated with 7.
Cancer therapy combining compound 7 and adoptive transfer of Vγ2Vδ2 T cells improves the 
survival of immunodeficient NOG mice inoculated with either human EJ-1 bladder carcinoma 
cells or HT1080 fibrosarcoma cells. Because BTN3A1 proteins and IPP-responsive γδ T cells are not 
present in mice, rats, guinea pigs, or rabbits, adoptive transfer models for human γδ T cell immunotherapy were 
developed. Immunodeficient NOG (NOD.Cg-Prkdcscid Il2rgtm1Sug/Jic) mice were intraperitoneally inoculated with 
either human EJ-1 bladder carcinoma cells or human HT1080 fibrosarcoma cells. Tumor-bearing mice were 
then injected twice a week with either (1) PBS, (2) compound 7, (3) γδ T cells, or (4) γδ T cells and compound 
7 until mouse death or euthanasia. The Vγ2Vδ2 T cells were derived from a single donor by stimulation with 
zoledronic acid, frozen for use, and were between 95–98% pure (Supplemental Fig. S6). Mice inoculated with 
EJ-1 cells survived longer when treated with γδ T cells and compound 7 (median survival 76 days) than with γδ 
T cells alone (median survival 60 days) (Fig. 6A, p = 0.0076). No increase in survival was noted after treatment 
with 7 compared with control mice (median survival 53 days versus 50.5 days for PBS, p = 0.4348). Similar results 
were noted with a second solid tumor, the HT1080 fibrosarcoma. Mice treated with γδ T cells and compound 7 
survived longer (median survival 73.5 days) than mice treated with γδ T cells alone (median survival 47.5 days) 
(Fig. 6B, p = 0.0008). Treatment with compound 7 alone did not prolong mouse survival (median survival 33.5 
days versus 37 days for PBS, p = 0.2879). 7 was well tolerated with no obvious morbidity and no mortality of mice 
given a 3–15-fold higher doses than those used in these experiments (Supplemental Fig. S7). These results show 
that combined treatment with γδ T cells and compound 7 improves survival of mice bearing two different human 
tumors and that a variety of tumors would be potentially responsive to treatment.
Discussion
Adoptive immunotherapy with Vγ2Vδ2 T cells for cancer has proven to be safe but of limited effectiveness. 
Treatment has resulted in partial and complete remissions and stable disease but most patients progress. In this 
study, we describe a new approach to therapy with Vγ2Vδ2 T cells by using bisphosphonate prodrugs where 
the phosphonate moiety is masked with pivoxil groups. Masking the phosphonate moiety greatly increases the 
potency of bisphosphonate stimulation of Vγ2Vδ2 T cells with several active at less than 100 nM. A thaizole com-
pound, 7 (tetrakis-pivaloyloxymethyl 2-(thiazole-2-ylamino)ethylidene-1,1- bisphosphonate), was particularly 
active, stimulating TNF-α release by Vγ2Vδ2 T cells at concentrations as low as 40 nM. 7 was significantly more 
potent than zoledronic acid at stimulating Vγ2Vδ2 T cells with an average EC50 that is 909-fold lower than zole-
dronic acid. Consistent with FDPS inhibition as its mechanism of action, 7 exhibited potent inhibitory activity 
for RAP1A prenylation in tumor cells (3,200-fold more active than zoledronic acid) and tumor cell growth43 
Tumor cell Origin
TNF-α EC50 (nM) Ratio
7 (PE) 14 (H) 7 EC50:14 EC50
786-0 Renal cell carcinoma 65 >100,000 1: >1,500
MKN1 Gastric cancer 560 89,000 1: 160
OST Osteosarcoma 600 >100,000 1: >170
PC-3 Prostate cancer 65 77,000 1: 1,200
PK1 Pancreatic cancer 450 >100,000 1: >200
LK-2 Squamous NSCLC 97 >100,000 1: >1,000
G-361 Melanoma 63 5,100 1: 81
TFK-1 Cholangiocarcinoma 66 >100,000 1: >1,500
MOLT-3 T cell acute lymphoblastic leukemia 66 >100,000 1: >1,700
MOLT-4 T cell acute lymphoblastic leukemia 59 >100,000 1: >1,300
PEER T cell acute lymphocytic leukemia 83 >100,000 1:>190
C1R B-cell lymphoma 530 >100,000 1: >1,200
SCC-3 Non-Hodgkin’s lymphoma 81 >100,000 1: >1,700
Raji Burkitt’s lymphoma 53 >100,000 1: >1,200
RAMOS-RA1 Burkitt’s lymphoma 140 >100,000 1: >1,500
U937 Acute monocytic leukemia 60 >100,000 1: >330
K562 Histiocytic lymphoma 80 >100,000 1: >1,900
THP-1 Erythroleukemia 300 >100,000 1: >700
HMC-1-8 Mammary carcinoma 920 >100,000 1:>110
YMB-1-E Mammary carcinoma 630 >100,000 1: >160
MRK-nu-1 Mammary carcinoma 180 >100,000 1: >560
Table 1. Effect of pivoxil esterification of 14 on TNF-α secretion from γδ Τ cells stimulated with 
bisphosphonate-pretreated tumor cells. The concentrations of compounds 7 (pivoxil ester prodrug) and 14 (acid 
form) required to stimulate half maximal TNF-α secretion (EC50) from γδ Τ cells in response to various tumor 
cell lines incubated with 7 or 14 are shown.
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(184-fold more potent than zoledronic acid). Like other FDPS inhibitors, 7 selectively stimulated Vγ2Vδ2 T cells 
to proliferate, secrete cytokines, and kill tumor cells treated with 7. Finally, combined therapy with 7 and Vγ2Vδ2 
T cells extended the survival of immunodeficient mice inoculated with either human bladder carcinoma or fibro-
sarcoma cells. Taken together, our results suggest that the bisphosphonate prodrug, 7, could significantly improve 
the efficacy of adoptive immunotherapy with Vγ2Vδ2 T cells.
To improve the activity of bisphosphonates, we designed and synthesized a series of bisphosphonate prodrugs43. 
In the present study, we have assessed bisphosphonate prodrug activation of Vγ2Vδ2 T cells and inhibition of 
RAP1A prenylation in response to a variety of human cancer cell lines pretreated with the compounds. Masking 
the negative charges of the phosphonate groups of bisphosphonates with pivoxil esters greatly increased their 
activity. However, biological activity varied between tumor cell lines. These variations could be explained by 
Figure 3. Stimulation of TNF-α secretion from γδ T cells by tumor cells pretreated with compound 7. (A–F) 
Stimulation of TNF-α production by γδ T cells in response to compound 7 pretreatment of various tumor 
cell lines; (A) lymphomas, ▫ MOLT-3, ∆ PEER, ⚪C1R, ⬧J.RT3-T3.5, ▪ Raji, ▴ RAMOS-RA1, ⚫MOLT-4; (B) 
myeloid leukemias, ▫ HL60, ∆ U937, ⚪THP-1, ⬧ SCC-3, ▪ P31/FUJ, ▴ K562,⚫ NOMO-1; (C) mammary 
carcinomas, ▫ YMB-1-E, ∆ MRK-nu-1, ○ HMC-1-8, ⬧ MCF-7, ▪ MDA-MB-231, ▴T-47D, ⚫ SK-BR-3; (D) 
renal cell carcinomas, ▴ 786-0, ∆ VMRC-RCZ, ⚫ UOK121, ⚪ Caki-1, ▪ A-704; (E) pancreatic carcinomas, 
⚫ BXPC-3, ▴ KP4-1, ⚪ KP4-2, ▫ KP4-3, ∆ MiaPaCa2; (F) other tumor cells, ⚫ TGB24TKB cholangiocell 
carcinoma, ▴ ACS gastric carcinoma, ⚪ MG63 osteocarcoma, ▫ LK-2 lung carcinoma, ∆ C32TG melanoma. 
(G) Comparison of compound 7 (left panel) with zoledronic acid (right panel) concentrations used to 
pretreat tumor cells for half-maximal stimulation of TNF-α production by Vγ2Vδ2 T cells. Ly = lymphomas, 
My = myeloid leukemia, Ma = mammary carcinomas, and Others = other tumor cell lines. Details of zoledronic 
acid stimulation of Vγ2Vδ2 T cells are from Idrees et al.46 and are included for comparison.
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differences in the levels of intracellular esterase activity and/or in the substrate specificity of the esterases52, 53. 
Additionally, differences in the levels of FDPS and which oncogenes were driving tumor cell proliferation and 
function could also play a role in determining their sensitivity to bisphosphonate prodrugs. Compound 7, a 
thiazole bisphosphonate prodrug, was highly active against most tumor cell lines. Hematopoietic cell lines were 
particularly sensitive to 7 averaging 796-fold more sensitive to 7 than zoledronic acid for growth inhibition, 
3,487-fold more active for TNF-α release by γδ T cells than zoledronic acid, and 12,869-fold more inhibitory for 
RAP1A prenylation than zoledronic acid. Thus, the bisphosphonate prodrug 7 could be particularly effective for 
the treatment of lymphomas and myeloid leukemias.
Figure 4. Inhibition of geranylgeranylation of RAP1A in tumor cells by compound 7. Tumor cells were 
cultured with 7 for 16 h, lysed, and the prenylation of RAP1A assessed after protein separation by SDS-PAGE, 
transfer to PVDF membranes, and probing with anti-unprenylated RAP-1A antibodies. (A–F) Compound 7 
inhibition of geranylgeranylation of RAP1A for various types of tumor cell lines: (A) lymphomas, ▫ MOLT-3, 
∆ PEER, ⚪ C1R, ⬧ J.RT3-T3.5, ▪ Raji, ▴ RAMOS-RA1, ⚫ MOLT-4; (B) myeloid leukemias, ▫ HL60, ∆ U937, 
⚪ THP-1, ⬧ SCC-3, ▪ P31/FUJ, ▴ K562, ⚫ NOMO-1; (C) mammary carcinomas, ▫ YMB-1-E, ∆ MRK-nu-1, 
⚪ HMC-1-8, ⬧ MCF-7, ▪ MDA-MB-231, ▴ T-47D, ⚫ SK-BR-3; (D) renal cell carcinomas, ▴ 786-0, ∆ VMRC-
RCZ, ⚫ UOK121, ⚪ Caki-1, ▪ A-704; (E) pancreatic carcinomas, ⚫ BXPC-3, ▴ KP4-1, ⚪ KP4-2, ▫ KP4-3, ∆ 
MiaPaCa2; (F) other tumor cells, ⚫ TGB24TKB cholangiocell carcinoma, ▴ ACS gastric carcinoma, ⚪ MG63 
osteocarcoma, ▫ LK-2 lung carcinoma, ∆ EJ-1 bladder carcinoma. (G) Comparison of compound 7 (left panel) 
with zoledronic acid (right panel) concentrations required for half-maximal inhibition of prenylation of RAP1A 
in tumor cells. Ly = lymphomas, My = myeloid leukemia, Ma = mammary carcinomas, and Others = other 
tumor cell lines. Data for zoledronic acid effects are from Idrees et al.46 and are included for comparison.
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One of the most important features of bisphosphonate prodrugs is their high membrane permeability that 
enables them to enter into tumor cells that have poor fluid-phase endocytosis. Because they were developed as 
anti-resorptive therapeutics, conventional bisphosphonates interact with hydroxyapatide crystals of bone with 
high affinity. In contrast, because of their hydrophobicity, bisphosphonate prodrugs will likely have low affinity 
for bone and, instead, distribute to non-skeletal tissues including tumors. The high membrane permeability and 
Figure 5. Selective activation of Vγ2Vδ2 T cells by compound 7. (A) Selective expansion of Vγ2Vδ2 T cells 
from blood αβ and γδ T cells after culture with compound 7. PBMC from a prostate cancer patient were 
stimulated with 1 μM compound 7 and IL-2. The two-color flow cytometric analysis of Vγ2Vδ2 T cells in PBMC 
before (left panel) and after (right panel) 10 day stimulation is shown. (B) Inhibition of EJ-1 bladder carcinoma 
cell growth by exposure to compound 7 and γδ T cells. Compound 7 was added to cultures of EJ-1 tumor cells 
followed by the addition of Vγ2Vδ2 T cell to some cultures16 h later. Cell growth was assessed in a real-time cell 
analyzer system. Culture conditions were: (1) 50 nM compound 7 + medium, (2) 0 nM compound 7 + γδ T cells, 
(3) 1.56 nM compound 7 + γδ T cells, (4) 12.5 nM compound 7 + γδ T cells, (5) 25 nM compound 7 + γδ T cells, 
(6) 50 nM compound 7 + γδ T cells. (C) Degranulation of γδ T cells in response to U937 histocytoma pretreated 
with compound 7. The proportion of CD107a+ degranulated Vδ2+ cells were plotted against the concentrations 
of compound 7 used for the pretreatment of U937 cells. (D) Stimulation of IFN-γ production by Vγ2Vδ2 T 
cells by compound 7. PBMC from healthy donor were cultured with 1 μM compound 7. After 48 h, the culture 
supernatants were removed and IFN-γ levels determined by ELISA.
www.nature.com/scientificreports/
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non-skeletal distribution of bisphosphonate prodrugs are ideal for their use in cancer immunotherapy targeting 
γδ T cells.
Clinical trials using adoptive immunotherapy with Vγ2Vδ2 T cells to treat various cancers have not routinely 
used bisphosphonate treatments to increase tumor immunogenicity27–36. However, the adoptive immunotherapy 
trials reporting the best results have also used zoledronic acid treatment. A complete remission in a patient with 
metastatic renal cell carcinoma (out of eleven patients treated) was achieved by treatment with intravenous zole-
dronic acid and IL-2 followed by adoptive transfer of Vγ2Vδ2 T cells on the same day and then intravenous IL-2 
given for four consecutive days repeated monthly for six cycles54. In a second trial, there were no responses noted 
in patients treated with zoledronic acid and γδ T cells alone but one complete remission was achieved in a breast 
cancer patient treated with a combination of zoledronic acid and adoptive transfer of Vγ2Vδ2 T cells along with 
the continuation of hormonal therapy30. Partial or complete responses were also noted in patients with various 
solid tumors when chemotherapy was combined with the adoptive transfer of Vγ2Vδ2 T cells with30 or without35 
zoledronic acid. Although stable disease was achieved in a number of patients with lung cancer55 and other solid 
tumors31, 35, 36, the most common response to the adoptive transfer of γδ T cells alone was progressive disease. 
Therefore, the combination of a nitrogen-containing bisphosphonate and γδ T cells appears more effective than 
either alone.
Combining bisphosphonate prodrugs with γδ T cells could significantly advance the use of γδ T cells for 
cancer immunotherapy for a wide range of tumors. Given the potency of compound 7 both for stimulating γδ 
T cells and for inhibiting tumor cell growth and its likely lowered bone binding and increased entry into rapidly 
metabolizing tumor cells compared with zoledronic acid, combination therapy with 7 and the adoptive transfer of 
γδ T cells could increase treatment efficacy. As shown in our study, Vγ2Vδ2 T cells respond to essentially all tum-
ors after treatment with compound 7 irrespective of the number of mutations the tumor harbors. Unlike TIL or 
CAR-T therapy, successful Vγ2Vδ2 T cell adoptive transfer does not require preconditioning with chemotherapy 
or irradiation. Therefore, therapy with 7 and γδ T cells could be further combined with checkpoint blockade with 
anti-PD-1/anti-PD-L1 and/or anti-CTLA-4 antibodies to activate anti-tumor CD4 and CD8 αβ T cells that are 
already present. Other cancer immunotherapies such as indoleamine 2,3-dioxygenase inhibitors56–58 or COX1/2 
blockers to inhibit prostaglandin E2 production59 could also be added. In summary, combining the bisphospho-
nate prodrug 7 and γδ T cells with other cancer immunotherapies could allow the treatment of a wide range of 
adult and pediatric solid tumors that are not presently amendable to successful chemotherapy or targeted therapy.
Figure 6. Combination therapy with compound 7 and γδ T cells prolongs survival of immunodeficient NOG 
mice inoculated with either human EJ-1 bladder carcinoma cells or human HT1080 fibrosarcoma cells. On 
day 0, NOG mice were inoculated i.p. with 1.0 × 106 EJ-1 or 1.0 × 106 HT1080 tumor cells that had been 
stably transfected with the luc2 luciferase. On day 3 and day 6, the mice were treated with either (1) PBS (⚪), 
(2) compound 7 (∆) (2 μg (97 μg/kg) for EJ-1 or 10 μg (485 μg/kg) for HT1080), (3) 2 × 107 γδ T cells (▴), or 
(4) 2 × 107 γδ T cells and compound 7 (⚫) (2 μg (97 μg/kg) for EJ-1 or 10 μg (485 μg/kg) for HT1080). This 
treatment regimen was repeated for the duration of the experiment. (A) Survival of mice inoculated with EJ-1 
cancer cells untreated or treated as above. Pooled data from two experiments performed identically is shown, 
n = 8 mice per group. (B) Survival of mice inoculated with HT1080 cancer cells untreated or treated as above. 
Pooled data from two experiments performed identically is shown, n = 8 mice per group except for mice treated 
with compound 7 where 4 mice were used. γδ T cells expressing Vγ2 Vδ2 TCRs (95–98% of transferred cells) 
were expanded from PBMC from a single donor and frozen for later use. Significance is shown for the survival 
difference between γδ T cells and compound 7 compared with γδ T cells alone as determined by the log-rank 
test.
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Materials and Methods
Synthesis of bisphosphonate prodrugs and their corresponding acid forms. The synthesis and 
chemical characterization of the bisphosphonate prodrugs and their acids used in these studies are described43.
Expansion of Vγ2Vδ2 T cells. Peripheral blood samples were obtained after approval of the institutional 
review board of Kyoto University Hospital and with written informed consent from all participants. All methods 
were performed in accordance with the relevant guidelines and regulations of Kyoto University Hospital. PBMCs 
were purified by Ficoll-PaqueTM PLUS (GE Healthcare Bio-Sciences AB, Uppsala, Sweden) gradient centrifuga-
tion. The cells were washed two times with PBS, then resuspended in modified Yssel’s medium supplemented with 
10% human AB serum (Cosmobio Co., Ltd., Koto-ku, Tokyo, Japan). They were cultured for 10 days at 2.5 × 106 
cells/1.5 ml in modified Yssel’s medium with 5 μM zoledronic acid and 100 IU/ml IL-2 (Shionogi Pharmaceutical 
Co., Ltd., Chuo-ku, Osaka, Japan) in a 24-well plate (Corning Inc., Corning, NY, USA). The culture medium was 
replaced every day from day 2 with fresh medium containing IL-2. The resulting expanded Vγ2Vδ2 T cells were 
then stored in liquid nitrogen for use upon thawing in in vitro assays or adoptive immunotherapy.
TNF-α release by Vγ2Vδ2 T cells. Tumor cell lines were grown, harvested, and resuspended at 1 × 106 
cells/0.5 ml in 10-fold serial dilutions of BP prodrugs or acid forms of BPs in complete RPMI 1640 media (Sigma, 
St. Louis, MO, USA) supplemented with 10% fetal calf serum (Sigma), 10−5 M 2-mercaptoethanol (Nacalai 
Tesque, Kyoto, Japan), 100 IU/ml penicillin (Meiji Seika Kaisha, Tokyo, Japan), and 100 μg/ml streptomycin (Meiji 
Seika Kaisha). After incubation at 37 °C with 5% CO2 for 4 h, the cells were washed three times with 5 ml of the 
medium and resuspended in 0.5 ml of the same medium. A total of 0.1 ml (2 × 105 cells/well) of the tumor cell 
suspension was placed on flat-bottomed 96-well plates and 0.1 ml of γδ T cells (2 × 105 cells/well) was added. The 
plates were incubated at 37 °C with 5% CO2 for 16 h and the culture supernatants stored overnight at −80 °C. The 
samples were then thawed and TNF-α concentrations determined by ELISA (Peprotech, Rocky Hill, NJ, USA) 
using an ARVO spectrophotometer (PerkinElmer, Foster City, CA, USA). All experiments were performed in 
triplicate. Because bisphosphonic acids are not efficiently internalized into some tumor cells and were sometimes 
cytotoxic to tumor cells at 0.1 mM or greater, it was difficult to calculate EC50 values for some cell lines. In these 
cases, the value at 0.1 mM was considered to be the maximum value and used to calculate arbitrary EC50 values.
Inhibition of geranylgeranylation of RAP1A in tumor cells. Tumor cells were resuspended in 
90 ml of complete RPMI 1640 medium supplemented with 10% fetal bovine serum (FBS, Sigma), 10−5 M 
2-mercaptoethanol (Invitrogen, Carlsbad, CA, USA), 100 IU/ml of penicillin (Meiji Seika Kaisha, Ltd., Chuo-Ku, 
Tokyo, Japan), and 100 μg/ml of streptomycin (Meiji Seika Kaisha) and grown overnight at 37 °C with 5% CO2 in 
225 cm2 flasks. Compound 7 was then added to the flasks to the concentrations indicated above. After incubation 
for 16 h, the cells were harvested and resuspended in 100 μl of lysis solution containing 1% NP-40 (Wako Pure 
Chemical Industries Ltd., Chuo-ku, Osaka, Japan), 0.1% sodium dodecyl sulfate (SDS) (Tokyo Chemistry Industry 
Co., Ltd., Chuo-Ku, Tokyo, Japan), and 0.5% sodium deoxycholate (Wako) in microcentrifuge tubes. After cen-
trifugation at 15,000 rpm for 10 min, the supernatants were transferred to new tubes and SDS-urea buffer con-
taining 6.7 M urea (Wako), 5% SDS, 100 mM Tris–HCl buffer, pH 7.4 (Wako), 0.25% bromophenol blue (Wako), 
and 50 mM dithiothreitol (Wako) was added to give a protein concentration of 5 mg/ml. The samples were loaded 
on 15% polyacrylamide slab gels (Daiichi Pure Chemicals Co., Ltd., Chuo-ku, Tokyo, Japan) at 50 μg/lane, and 
electrophoresed at 120 mA/h. The proteins were then transferred onto Polyscreen (R) PVDF Transfer Membranes 
(PerkinElmer Inc., Waltham, MA) treated with goat anti-unprenylated RAP1A mAb (1 to 500 dilution, Santa 
Cruz Biotechnology Inc., Santa Cruz, CA, USA), and horse radish peroxidase-conjugated anti-goat IgG mAb 
(1 to 5,000 dilution, KPL Inc., Gaithersburg, MD, USA), followed by SuperSignal West Pico Chemiluminescent 
Substrate (Thermo Scientific, Rockford, IL, USA). Although not shown, controls using goat anti-RAP1A and 
anti-GAPDH mAbs (Santa Cruz Biotechnology) were included in this study. Chemiluminescence was detected 
on Amersham HyperfilmTM MP (GE Healthcare Ltd., Little Chalfont, Buckinghamshire, UK) using a Fuji Medical 
Film Processor FPM100 (Fuji Film Co., Ltd., Ashigara, Kanagawa, Japan). The strength of the signal for each 
protein band was determined by the brightness of the corresponding part of the image scanned using a LAS-4000 
Mini Luminescent Image Analyzer (Fuji Film Co., Ltd.). The dose-response curves are based on the digitalized 
data.
γδ T cell activation assays. For expansion of Vγ2Vδ2 T cells, PBMC from healthy donors were cultured at 
2.5 × 106 cells/1.5 ml in modified Yssel’s medium in the presence of 1 μM compound 7 in a 24-well plate (Corning 
Inc., Corning, NY, USA). The culture medium was replaced on day 2 with fresh medium containing IL-2. The 
cells were passaged on days 7, 9, 10, 11, and 12 and IL-2 (100 IU/ml) was added to the culture medium every day 
beginning from day 1. On day 14, the cells were harvested and analyzed for the expression of CD3 and Vδ2 by 
flow cytometry. For measurement of interferon-γ (IFN-γ) release, PBMC from healthy donors were cultured at 
2.5 × 106 cells/1.5 ml in modified Yssel’s medium in the presence of 1 μM compound 7 at 37 °C with 5% CO2 in a 
24-well plate (Corning Inc., Corning, NY, USA). After 24 h, 100 IU/ml IL-2 (Shionogi Pharmaceutical Co., Ltd., 
Chuo-ku, Osaka, Japan) was added to the culture medium. After an additional 24 h, the culture supernatants were 
removed and stored overnight at −80 °C. The samples were then thawed and IFN-γ levels determined by ELISA 
(Peprotech, Rocky Hill, NJ, USA). All experiments were performed in triplicate.
Inhibition of in vitro tumor cell growth by compound 7 and Vγ2Vδ2 T cells. Inhibition of cell 
growth by compound 7 and Vγ2Vδ2 T cells was measured using a real-time cell analyzer (RTCA) system com-
prising a 96-well E-plate with impedance sensors. Tumor cells were cultured for 24 h, harvested using 0.25% 
trypsin-EDTA solution (Invitrogen Gibco), and plated into 96-well E-plates at a density of 3 × 103 cells/100 μl/
well. Impedance was monitored every 15 min for 46.5 h at 37 °C with 5% CO2. 50 μl of supernatant was then 
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removed from, and 50 μl of a serial dilution of compound 7 was added to each well. The plates were returned 
to the RTCA unit and incubated at 37 °C with 5% CO2 for 3.5 h. After 50 μl of the supernatant was removed, 
1 × 105 Vγ2Vδ2 T cells/50 μl were added to each well. Impedance was monitored for an additional 15 h. Five 
independent replicate experiments were performed, with eight wells per treatment group used in each individual 
replicate experiment.
CD107a degranulation assay. Vγ2Vδ2 T cells (2 × 105 cells/well) were incubated with U937 cells (2 × 105 
cells/well) that had been treated with serial dilutions of compound 7 for 2 h at 37 °C in 50 μl of complete RPMI 
1640 medium in a 96-well culture plate in the presence of 5 μl of phycoerythrin-conjugated anti-CD107a mAb 
(BioLegend, San Diego, CA, USA) at 37 °C with 5% CO2. After 4 h of incubation, the cells were stained with 50 μl 
of 25-fold diluted FITC-conjugated anti-Vδ2 mAb fluorescein isothiocyanate-conjugated anti-TCR-Vδ2 mAb 
(Immunotech, Prague, Czech Republic) and analyzed using a FACSCalibur flow cytometer. The proportion of 
CD107a+ cells in Vδ2+ cells was plotted against concentrations of compound 7.
Inhibition of tumor cell growth by treatment with compound 7 and γδ T cells in NOG immuno-
deficient mice. Immunodeficient NOG (NOD.Cg-Prkdcscid Il2rgtm1Sug/Jic) female mice 7–8 weeks of age were 
intraperitoneally (i.p.) inoculated with either 1.0 × 106 EJ-1 bladder cancer cells or 1.0 × 106 HT1080 fibrosar-
coma cells that had been stably transfected with pGL4.10[luc2] (Promega) to express the luc2 luciferase protein. 
On day 3 and 6, tumor-bearing mice were i.p. injected with either (1) 0.1 ml of PBS, (2) 2 μg (for EJ-1) or 10 μg (for 
HT1080) compound 7, (3) 2 × 107 γδ T cells, or (4) 2 × 107 γδ T cells plus 2 μg (for EJ-1) or 10 μg (for HT1080) 
compound 7. A dose of 2 μg of compound 7 corresponds to 97 μg/kg whereas 10 μg corresponds to 485 μg/kg. 
These treatment regimens were repeated for the duration of the experiment. Survival of the mice was recorded 
and plotted using Prism version 4.0 c. Vγ2Vδ2 T cells were expanded for 10 days from PBMC from a single donor 
with breast cancer as described above and frozen for use. Purity of the Vγ2Vδ2 T cells was between 95–98%. 
Animal use was approved by the institutional review board of Kyoto University Medical School. All methods 
were performed in accordance with the relevant guidelines and regulations of Kyoto University Medical School.
Statistical analyses. The statistical significance of survival data was assessed using the log-rank test. The 
p values are shown in the figure. The Pearson correlation coefficient was determined by correlating the different 
biological activities of compound 7 and zoledronic acid. p < 0.05 was considered significant. Statistical analyses 
were done in Prism version 4.0c (GraphPad Software, La Jolla, CA).
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